In contrast to the previous findings [169,170] both low baseline butyrate and low baseline propionate (in serum) were correlated with longer PFS in metastatic melanoma patients treated with anti-CTLA-4 antibodies [172]. Here, CTLA4 is linked to metastatic melanoma.